CLINICAL ROLE -
EP. 1: Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer
Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors.
Watch
EP. 2: Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer
Aimee Keegan, PharmD, BCOP, discusses how her institution optimizes patient adherence to CDK4/6 inhibitors, highlighting resources including their in-house specialty pharmacy.
EP. 3: CDK4/6 Inhibitors as First-Line Options in Metastatic Breast Cancer
Expert perspectives on differentiating between the three CDK4/6 inhibitors available for the treatment of metastatic breast cancer are discussed, highlighting factors that inform treatment selection.
EP. 4: Treatment Algorithms for Early and Metastatic Breast Cancer
A clinical pharmacist details how treatment algorithms differ between early-stage and metastatic breast cancer.
EP. 5: NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast Cancer
Aimee Keegan, PharmD, BCOP, discusses key unmet needs that the NATALEE trial addresses for patients with HR+/HER2- early breast cancer.